CGON Cg Oncology Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: CGON

Price (delayed)

$56.27

Market cap

$4.96B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.33

Enterprise value

$4.94B

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 82
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 6

We are a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Our product candidate, cretostimogene, is initially in ...

Highlights
CGON's equity has surged by 55% year-on-year and by 45% since the previous quarter
The quick ratio has grown by 27% from the previous quarter
The gross margin has plunged by 150% YoY
Cg Oncology's net income has shrunk by 77% YoY and by 16% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://cgoncology.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of CGON

CGON stock price

How has the Cg Oncology stock price performed over time
Intraday
3.4%
1 week
-7.34%
1 month
-16.88%
1 year
111.7%
YTD
35.53%
QTD
-16.86%

Financial performance

How have Cg Oncology's revenue and profit performed over time
Revenue
$5.07M
Gross profit
-$2.54M
Operating income
-$214.96M
Net income
-$186.75M
Gross margin
-50%
Net margin
-3,682.6%
The gross margin has plunged by 150% YoY
Cg Oncology's operating margin has surged by 79% YoY and by 10% QoQ
Cg Oncology's net margin has surged by 77% YoY and by 8% QoQ
Cg Oncology's net income has shrunk by 77% YoY and by 16% QoQ

Price vs fundamentals

How does CGON's price correlate with its fundamentals

Growth

What is Cg Oncology's growth rate over time

Valuation

What is Cg Oncology stock price valuation
P/E
N/A
P/B
4.35
P/S
937.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
973.58
CGON's EPS has plunged by 54% YoY and by 12% from the previous quarter
CGON's equity has surged by 55% year-on-year and by 45% since the previous quarter
The price to book (P/B) is 2.1% lower than the last 4 quarters average of 4.3
The stock's P/S is 48% less than its last 4 quarters average of 1735.3
CGON's revenue is up by 26% since the previous quarter

Efficiency

How efficient is Cg Oncology business performance
CGON's ROS has soared by 77% YoY and by 8% from the previous quarter
The ROE has declined by 40% year-on-year
The company's return on assets fell by 37% YoY
Cg Oncology's return on invested capital has decreased by 24% YoY

Dividends

What is CGON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CGON.

Financial health

How did Cg Oncology financials performed over time
Cg Oncology's total liabilities has surged by 86% YoY and by 12% QoQ
Cg Oncology's total assets has soared by 56% YoY and by 43% from the previous quarter
Cg Oncology's debt is 99% lower than its equity
CGON's equity has surged by 55% year-on-year and by 45% since the previous quarter
Cg Oncology's debt has increased by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.